Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal is to gain insight in the development and course of the toxicity after a curative treatment of prostate cancer
All with curative intent treated prostate cancer patients will be enrolled in the SFP (Standard Follow-up Programme). It also includes the post -operative adjuvant treatments and the patients with positive lymph nodes.
Patients will complete weekly questionnaires to score the patient -rated toxicity. Biweekly patients are seen by the treating radiation oncologist and / or AIOS in which the physician -rated toxicity is scored. In the follow-up will always patient -rated toxicity and physician -rated toxicity can be determined.
Use of an SFP should yield a profit for the practitioner , such as the automatic generation of letters. This should apply to all SFPs .
Quality of life and toxicity in patients will be completed on the touch-screen computers at FU visits.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| 1. Change in Acute toxicity | Common Terminology Criteria for Adverse Events, version 4.0
| Toxicity:First visit/Wekely during RT, Acute Toxicity: 2-wekely and at the end of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT |
| Measure | Description | Time Frame |
|---|---|---|
| 2. Change in patient -rated Quality-of-Life | Questionnarys QLQ-PR25, QLQ-C30, International Index of Erectile Function | First visit/End of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT |
| Measure | Description | Time Frame |
|---|---|---|
| 3. Change in physiological parameters | PSA and Testosteron | First visit/2 months after RT/1, 2, 3, 4, 5 years after RT |
| 4. Change in Acute/ Late toxicity(physician rated) | Common Terminology Criteria for Adverse Events, version 4.0
|
Inclusion Criteria:
Exclusion Criteria:
Patients who are not willing to fill in toxicity and QOL-questionnarys Patients who will not get RT Non-curative or palliative treated patients (with bone mestasis) Non-prostate cancer-patients
Not provided
Not provided
Not provided
All with curative intent treated prostate cancer patients who will be treated with RT will be enrolled in the SFP.
It also includes the post-surgical adjuvant treatment and patients with positive lymph nodes to research the development and toxicity after RT
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| S. Aluwini, MD PhD | Contact | +31503612346 | s.al-uwini@umcg.nl | |
| P. Veldhuijzen van Zanten | Contact | +31503614659 | p.veldhuijzen@umcg.nl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Center Groningen | Recruiting | Groningen | 9700RB | Netherlands |
Sharing data between physicians at the Department of Radiotherapy
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| First Visit/ 2 wekely/ End of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |